FDA
-
-
-
-
-
-
-
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
-
-
-
-
-
-
-
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
-
-
-
-
-
-
-
Eledon Pharmaceuticals (ELDN) Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
-
-
-
-
-
-
-
Eledon Pharmaceuticals Provides Business and Pipeline Updates
-
-
-
-
-
-
-
Eledon Pharmaceuticals (ELDN) Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy
-
-
-
-
-
-
-
Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients
-
-
-
-
-
-
-
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results
-
324,317 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

